Across TCGA pan-cancer cohorts, MIR125B1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR125B1 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MIR125B1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR125B1 expression acts as an unfavorable survival marker.

BLCA and SKCM are the cancer types where MIR125B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.174	0.625	.023	12	view →
SKCM	DFS	Median	All	0.198	0.737	.021	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIR125B1 tumor-vs-normal RNA expression · all MIR125B1 data types